Biomarker Technologies Market - Global Forecast to 2022
The link to the original content can be found at the end of our message below.
In the past Forimmediaterelease circulated releases distributed through the Cision and PR Newswire system on a complimentary basis and as a service to our readers.
PR Newswire now claims copyright on press releases distributed through the Cision and PR Newswire system.
Their pitch: “Share your brand’s story around the world,” but that’s where it ends. When eTN, as a media outlet for travel and tourism news, tried to publish a release distributed to journalists by PR Newswire, they were told the release must be removed immediately. In addition, PR Newswire threatened eTurboNews with their legal counsel claiming copyright of releases from PR Newswire or Cision circulates on behalf of clients.
Here is the letter received by eTurboNews from a PR Newswire/Cision director:
“Subject: removal request
Please immediately remove the following posting from your site: [website name removed]
PR Newswire distributed this release on behalf of our client [client name removed]
[company name removed] is understandably upset that the release is posted on your site, tagged with Travel & Tourism Industry release: at the start of the text.
As you can see below in the release that we distributed that we did not include any coding or tagging on our end to indicate that the release is relevant to the Travel & Tourism industry: [website link removed]
Please completely remove the posting from your site as soon as possible, and confirm when complete.
Additionally, I am unable to find a licensing agreement between PR Newswire and eTN, or any other associated websites. If you do have a licensing agreement in which PR Newswire has licensed your sites to publish our content, please send a copy to me as soon as possible.
If you do not have a licensing agreement, we request that you remove all PR Newswire content from all of your sites. If I should have our Counsel send an official request, please let me know to whom it should be resent.
Director CISION PR Newswire”
It appears PR Newswire is not only charging a steep amount of money from companies wanting their releases circulated through their system to journalists but also is now trying to license this content as their copyrighted material. eTN receives more than 2,000 story ideas on a daily basis, we don’t rely on PR Newswire for content, and for sure we won’t pay them a licensing fee for a ‘privilege’ to publish such content.
We urge everyone using PR Newswire services to take a look at this article explaining their modus of operation and misleading reports: http://buzz.travel/prn/ .
PR Newswire is now directly competing with publications. This will result in a drastic drop in pick-ups. They are obviously upset with the attention we received for stoties and the visibility we were able to record way ahead of PR Newswire when it comes to our industry segment.
Journalists of any publication should be warned to consider taking content from PR Newswire or Cision.
Therefore, in the future, if you would like us to consider your press releases for publication, you will need to send it to us directly: For more information, visit: www.buzz.travel .
As a courtesy to our readers, you can find the original release content at:
DUBLIN, May 16, 2018 /PRNewswire/ —
The “Biomarker Technologies Market by Profiling Technology (Chromatography, NGS, PCR, Mass Spectrometry, Immunoassay, Liquid Biopsy), Research Area (Proteomics, Lipidomics), Application (Biomarker Validation & Discovery) – Global Forecast to 2022” report has been added to ResearchAndMarkets.com’s offering.
The biomarker technologies market is expected to reach USD 74.51 Billion by 2022 from USD 46.97 Billion in 2017, at a CAGR of 9.7% during the forecast period.
While significant advances have been made in the area of biomarkers, translating them into useful clinical assays is tedious and a prime hurdle to the clinical use of these biomarkers. The growth of this market is driven by factors such as increasing healthcare expenditure, increase in R&D funding, and the increasing utility of biomarkers for diagnostic purposes, and rising biomarker research.
Based on product type, the biomarker technologies market is classified into consumables, instruments, services, and software/informatics. In 2017, the consumables segment was expected to account for the largest share of the market due to their larger sales volume as compared to instruments. The consumables market is further segmented into reagents & kits and chromatography columns. In 2017, the reagents & kits segment accounted for the largest share of the consumables market.
By profiling technology, the biomarker technologies market is classified into immunoassay, PCR, imaging technology, mass spectrometry, NGS, chromatography, cytogenetics, and other technologies. The immunoassay segment accounted for the largest share in 2017. This segment is further divided into ELISA, western blot, and protein microarray.
In 2017, the ELISA segment accounted for the largest share of the immunoassay market. ELISA can simultaneously quantify levels of multiple proteins and have the potential to accelerate the validation of protein biomarkers for clinical use. Such factors are increasing the use of ELISA for confirmatory studies in biomarker discovery.
In 2017, North America accounted for the largest share of the biomarker technologies market. Asia Pacific is expected to register the highest growth from 2017 to 2022 for the biomarker technologies market. Factors such as the rising incidence of cancer, growing geriatric population, and support from private and public organizations for biomarker research are driving the growth of this regional segment.
Key Topics Covered:
1 Biomarker Technologies Market: Introduction
2 Biomarker Technologies Market: Research Methodology
3 Biomarker Technologies Market, By Test Type
3.2 Solid Biopsy
3.3 Liquid Biopsy
4 Biomarkers Liquid Biopsy Market, By Application
4.2 Clinical Diagnostics
4.4 Drug Discovery and Development
5 Liquid Biopsy Market, By Technology
5.3 Mass Spectrometry
6 Biomarker Technologies Market, By Product
7 Biomarker Product Market, By Application
22.214.171.124 Clinical Use
7.1.2 Drug Discovery & Development
126.96.36.199 Clinical Use
7.2.2 Drug Discovery & Development
188.8.131.52 Clinical Use
7.3.2 Drug Discovery & Development
184.108.40.206 Clinical Use
7.4.2 Drug Discovery & Development
8 Biomarker Technologies Market, By Profiling Technology
8.1.2 Western Blot
8.1.3 Protein Microarray
8.3 Mass Spectrometry
8.6 Imaging Technologies
9 Biomarker Profiling Technology Market, By Application
9.3 Mass Spectrometry
9.5 Imaging Technologies
10 Biomarker Disease Indication Market, By Application
10.1.2 Drug Discovery & Development
10.2 Infectious Diseases
10.2.2 Drug Discovery & Development
10.3 Autoimmune Disorders
10.3.2 Drug Discovery & Development
10.4 Neurological Disorders
10.4.2 Drug Discovery & Development
10.5 Cardiovascular Disorders
10.5.2 Drug Discovery & Development
10.6.2 Drug Discovery & Development
11 Biomarker Technologies Market, By Application
11.1 Biomarker Identification, Validation & Development Research
11.2 Routine Biomarker-Based Tests
12 Biomarker Technology Applications Market, By Product
12.1 Biomarker Identification, Validation & Development Research
12.2 Routine Biomarker-Based Tests
13 Biomarker Technologies Market, By Research Area
13.3.1 Metabolic Flux
13.4 Other Research Types
14 Market Share Analysis
14.1 Biomarker Technologies Market for Mass Spectrometry: Market Share Analysis
14.2 Biomarker Technologies Market for Chromatography: Market Share Analysis
15 Biomarker Technologies Market, By Region
- Agilent Technologies (US)
- Thermo Fisher Scientific (US)
- Roche (Switzerland)
- Waters Corporation (US)
- Danaher Corporation (US)
- Shimadzu Corporation (Japan)
- Bio-Rad Laboratories (US)
For more information about this report visit https://www.researchandmarkets.com/research/tx3xs4/biomarker?w=5
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
To post and circulate your own press release on FIR and the eTN Network please click here
Comments are closed here.